Open Technologies

This is a cell line derived from explanted cultures of human lung cancer tissue. This cell line has been tested by the FDA.

A novel class of amphiphilic amines (RCn) as antitumor agents and nanocarriers.

Discover new therapeutic targets against antibiotic resistant pathogens to identify novel antibiotic targets.

This technology pertains to molecular mechanisms and/or signaling pathways involved in tumorigenesis, angiogenesis and metastasis of breast cancer and its response to therapy.

This technology pertains to bodipy conjugated tyrosine kinase inhibitors that are currently used in the clinic for the treatment of CML or gastric cancers.

This technology pertains to small molecule inhibitors of RNase H1, especially in regards to genome instability, transcription, and translation.

This technology provides a non-invasive way to diagnose skin cancers, either benign or malignant.

This technology describes the specific detection and destruction of tumor cells using photodynamic therapy, with a focus on breast cancer.

This technology pertains to safe and effective TEM5 agonists and/or antagonists that modulate WNT signaling.

This technology is a device used to hold transmission electron microscopy grids that allows adherent mammalian cells to grow.

DNA methylation profiling of many genes that have been identified for use in diagnosis and staging of osteoarthritis, as well as prognostication of future propensity to develop osteoarthritis

Engineered Pseudomonas for biotechnological applications

Engineer new Pseudomonas aeruginosa  that specifically target and destroy cholesteatoma cells.

The genetically enhanced Pseudomonas aeruginosa transforms wastewater into electricity and valuable byproducts.

This technology has to a non-naturally occurring nucleic acid molecule with a sequence encoding a peptide or a DNA-binding polypeptide; including a nucleic acid binding domain and more.

This technology pertains to a ground squirrel iPSC line that can be differentiated into many different cell types for hibernation studies, disease modeling, and drug screening.

The new fenretinide-carrier molecules soluble-in- water complexes.

Research is underway with pediatric DIPG.

This technology provides a method that is used to detect copper in living cells in humans.

This technology pertains to GATA-3 function and dysregulation during the onset and progression of breast cancer that may lead to new strategies in diagnosing and treating the disease.

This technology pertains to an allograft that resembles human-like melanoma and has features that will stimulate a normal immunological response in the mouse.

GeRM protects genetically modified organisms from unauthorized use or release into the environment

This technology provides a diagnostic tool that can identify new drugs that increase chromosome instability.

This technology pertains to a human antibody that could be used safely in vitro and in vivo for the detection of CH2, Fc, and IgG.

This technology pertains to transgenic mice that have immunocompetent rat growth hormone-firefly Luciferase-enhanced green fluorescent protein (GFP) for use in tracking tumor progression.

Pertaining to antibodies which specifically bind to immunogenic memapsin 2 β-secretase peptides used in treatment of Alzheimer's disease and memapsin 2 β-secretase disorders

This technology pertains to specific rabbit monoclonal antibodies generated against the ErbB4 receptor (also known as HER4) that have been validated for specificity using tissue sections and extracts from ErbB4 knockout mice.

This technology pertains to research materials for improved production of prenylated proteins.

This technology provides a method for live imaging of lymphatic tissues.

This technology pertains to surfactant modulating agents for the treatment of surfactant related lung disorders.

This technology pertains to twelve lentiviral vectors that express both fluorescent and luminescent markers as a single fusion protein under various gene promoters.

This technology features a Serous Epithelial Ovarian Cancer (SEOC) genetically engineered mouse model (GEM), GEM-derived SEOC orthotopic mouse model, and biological materials derived therefrom.

This technology describes methods for generating gradients that offer unique profile intensities, unique profile shapes, or tunability.

Methods for diagnostic assays via the detection of carbohydrate antigens and associated autoantibodies that are indicative of the presence of IBD's, such as ulcerative colitis or Crohn's Disease.

This technology pertains to unique agents that target fungal invasion processes.

This technology describes the inhibition of NEDD8 activity by inhibiting the binding of NEDD8 E2 enzymes using small molecules and peptides to treat cancer.

This technology describes a novel combination of chemicals that may be used for corneal transplants.

This technology describes a specific diagnostic tool and potential therapeutic target for Ewing's sarcoma.

This technology describes a method of treatment for adult and pediatric Ph+ ALL.

This technology relates to compositions and methods for treating some autoimmune diseases, mainly Sjögren's syndrome.

This technology treats glucocorticoid resistant cancers, particularly acute Lymphoblastic Leukemia. This technology also includes a diagnostic tool.

This technology focuses on a treatment for breast cancer and melanoma.

This technology uses Selenium as a potential chemo and radio sensitizer for colon cancer, lung cancer, and breast melanoma.

Method of inhibiting vascular leakage in central nervous system (CNS) tissues comprised of administering an agonist or mimic of Podoplanin

This technology pertains to a mouse model that shows a pre-clinical therapeutic response of residual metastatic disease.

This technology is a new mouse model for monoclonal antibodies and immunoconjugates that target malignant mesotheliomas.

This technology pertains to orthotopic allograft models for pancreatic cancer that utilize cells or tumor fragments implanted into the cancer-free pancreata of recipient immunocompetent mice.

This technology pertains to Crocetin and how it may inhibit pancreatic cancer cell proliferation and induces apoptosis in pancreatic cancer cells.

This technology pertains to gp120 and CD4-induced antibody fusion proteins for use in an HIV vaccine.

This technology pertains to the synthesis of S-alanyl-glutathione (glutathionine) in the pathway of sulfur amino acid metabolism.

A potential treatment of MS by decreasing the concentration of adenosine in the brain vasculature or treatment with an adenosine receptor antagonist.

oHSV-Gluc forces tumor cells to secrete Gaussia luciferase (GLuc) as a detectable biomarker

This technology pertains to diagnostic methods for the detection of breast cancer using spatial genome organization.

This technology pertains to the detection of weak molecular complex interactions for research and commercial use.

This technology pertains to nanoparticles that can be used for imaging and drug delivery simultaneously to potentially treat cancer and heart disease.

Inhibition of the Bright transcription factor to produce pluripotent stem cells that can differentiate into all tissue types

This technology is useful for detecting rat acetylserotonin methyltransferase in immunological assays.

This technology describes nanoparticle coatings that are water dispersible for the treatment of cancer.

This technology describes a mode of delivery with improved formulation that allows for detecting or treating cancer cells.

This technology pertains to immunoglobin (Ig) promoters, in particular murine Ig promoters, to function differentially.

This technology pertains to highly selective Hsp90ß inhibitors that can be developed for the treatment of a variety of diseases that result from increased Hsp90 expression.

This technology is a computer software suite that enables its user to investigate extremely large experimental datasets in a simple, yet multidimensional, manner.

This technology describes the use of SORS to discriminate multiple layers of soft tissue for identification.

This technology pertains to mouse epithelial cancer cell lines that could be further developed or commercialized.

This technology pertains to methods and compositions relating to the identification, stimulation, and repression of stem cells that express Toll-like receptors

This technology describes the use of NADPH levels to differentiate between healthy and diseased tissue.

Specific genes and combinations thereof that contribute to systemic lupus erythematosus, including methods of diagnosis and treatments targeting those genes.

This technology pertains to the genotypic and phenotypic analysis of the 888 mel cell line in order to better understand the nature of tumor cells that respond to therapy.

The Therapoid™ platform is an online ecosystem which enables members of the biotechnology community to connect, network, and collaborate for the advancement of science.

This technology is an improved cell line called Tni-FNL, which is capable of high level expression of heterologous proteins using baculovirus expression systems.

This technology is a characterized transgenic model that is currently an excellent mouse model for TNBC that shares important molecular characteristics of human TNBC.

This technology describes a model pertaining to in vitro drug testing for metastatic cancers.

This technology pertains to patient-derived gastrointestinal tumors (GIST) and paraganglioma tumors that harbor genetic mutations that have an effect on early stage embryogenesis.

This technology is useful for the investigation of the mechanisms of phosphodiesterase inhibition.

This technology uses the UOK 262 immortalized cell line as research tool to study aggressive hereditary leiomyomatosis and renal cell carcinoma (HLRCC) associated with recurring kidney cancer.

Methods of making water soluble GPCR proteins that provide a greater surface area for signal transduction.